Management of stage I testis cancer.

I-4: Male Fertility Preservation Options, Current State-of-The ART and Future Implications

Background Male infertility management has made significant progress during the past three decades, especially after the introduction of intracytoplasmic sperm injection (ICSI) in 1992. However, many boys and men still suffer from primary testicular failure due to acquired or genetic causes. New and novel treatments are needed to address these issues. Spermatogenesis originates from spermatogon...

Current role of retroperitoneal lymph node dissection in testicular cancer.

Carcinoma of the testis is the most common malignancy in males 15 to 35 years of age. Testicular cancer has become one of the most curable solid neoplasms and as such, serves a paradigm for the multimodality treatment of malignancies. The cure rate for patients with clinical stage I disease is nearly 100%, and patients with advanced disease now achieve complete remission rates of over 90%. The ...

Infrequent Expression of the Cancer-Testis Antigen, PASD1, in Ovarian Cancer

Ovarian cancer is very treatable in the early stages of disease; however, it is usually detected in the later stages, at which time, treatment is no longer as effective. If discovered early (Stage I), there is a 90% chance of five-year survival. Therefore, it is imperative that early-stage biomarkers are identified to enhance the early detection of ovarian cancer. Cancer-testis antigens (CTAs),...

Treatment options for clinical stage 1 testis cancer.

Management of Nonseminomatous Germ Cell Tumor of the Testis

About 5-7/100,000 men are diagnosed with testis cancer annually. A large proportion of these are pathologically classified as non-seminomatous germ cell tumor (NSGCT). The majority of NSGCT patients present with clinical stage (CS) I disease, which is characterized by a germ cell tumor confined to the testis, a negative metastatic work-up which includes a chest X-ray (CXR), computed tomography ...